The U.S. Food and Drug Administration said that it approved Cosentyx, a new psoriasis drug from Novartis AG to treat adults with moderate to severe cases of the dermatologic disease. The drug is seen by some analysts as a potential blockbuster, as psoriasis afflicts more than 125 million people world-wide.
via WSJ.com: US Business http://ift.tt/1E2VoyC
via WSJ.com: US Business http://ift.tt/1E2VoyC
Nessun commento:
Posta un commento